Tech to control expression of metabolism-regulating SESTRIN proteins aims to strengthen longevity and wellness IP pipeline.
Leonhardt Ventures, and its commercial distribution arm Lionheart Health, has filed a series of patent claims for bioelectric controlled expression of the SESTRINs family of antiaging proteins based on data from its affiliated R&D lab in Irvine, California.
Longevity.Technology: Sestrins are a family of highly conserved stress-responsive proteins that have been identified in numerous studies as having powerful antiaging properties. Studies have demonstrated that increased circulating sestrins can help increase the benefits of exercise in a shorter exercise time. As well as possibly preventing atrophy of muscles through disuse or aging, sestrins exhibit cardioprotective actions to help prevent the heart from damage. Sestrins also appear to play a key role in preventing or reversing aging-related skin wrinkles and may help to prevent hair loss. Due to their ability to counter oxidative stress, sestrins may have a significant role in staving off neurodegenerative disorders such as Alzheimer’s, Parkinson’s and memory loss.
Sestrins are clearly important proteins, so it is no wonder that Leonhardt Ventures is engaged in research that is exploring many of these potential useful applications of its patent-pending tech.
“In our R&D lab studies that fed the data to support this pioneering patent application we have demonstrated repeated reliability of increasing selected SESTRIN protein family expressions by up to 190% with only 30 minutes of stimulation time across a variety of tissue and cell types including muscle derived myoblasts,” said Dr Jorge Genovese VP of Bioelectric Regeneration Research at Leonhardt Ventures, Leonhardt’s Launchpads and Lionheart Health, Inc.
“These studies included precise controlled frequency, current intensity, pulse duration, pulse width and shape to get these optimal expression results. We look forward to now to the hard work to translate these exciting lab results into helping people fight back many of devastating effects of aging and disease .”
Sestrins are metabolic proteins, and are known to protect against DNA damage, oxidative stress, starvation, endoplasmic reticulum (ER) stress, and hypoxia. Sestrins regulate metabolism mainly through activation of the key energy sensor AMP-dependent protein kinase (AMPK) and inhibition of mammalian target of rapamycin complex 1 (mTORC1).
They also play pivotal roles in autophagy activation and apoptosis inhibition in normal cells, while conversely promoting apoptosis in cancer cells. The functions of Sestrins in diseases such as metabolic disorders, neurodegenerative diseases, cardiovascular diseases and cancer have been broadly investigated in the past decades, and The Leonhardt Ventures team is aiming to translate some of these well investigated applications into clinical use and helping patients have better outcomes.
This patent filing adds to the long list of Leonhardt organ regeneration, longevity, wellness and healing bioelectric protein expression patent claims issued or pending which include klotho, inflammation management, kidney, skin, bone, muscle and nerve regeneration, hypertension management and knee osteoarthritis and diabetes treatments.
Leonhardt is also the company behind BodStim, a bioelectric body exercise suit with FDA clearance for augmenting the benefits of exercise by increasing circulating Klotho, a powerful antiaging and muscle regeneration protein.
“We are an innovation team that continuously works on strengthening our intellectual and technology platform, ” said Howard Leonhardt, Executive Chairman, CEO and Co-Inventor. “This new patent filing adds to a long pipeline of data driven invention discoveries to help extend longevity and wellness. Our goal is to be the recognized world leader in longevity and wellness technology development and delivery. Our team focuses its regenerative medicine research work at the convergence of bioelectric protein expression controls and biologics .”